Tags

Type your tag names separated by a space and hit enter

[Anti-deamidated gliadin peptides antibodies and coeliac disease: state of art and analysis of false-positive results from five assays].
Ann Biol Clin (Paris) 2010 Mar-Apr; 68(2):149-56AB

Abstract

Recently, anti-deamidated gliadin antibodies were proposed for the serological diagnosis of celiac disease. We evaluate the specificity of different anti-deamidated gliadin antibodies ELISA in comparison with conventional anti-native gliadin kits. Serum samples from 46 non celiac patients were analyzed by five different quantitative ELISA for anti-native gliadin, anti-deamidated gliadin and anti-transglutaminase neo-epitope antibodies together with a screening ELISA. Twenty-four percent of the patients demonstrated anti-native gliadin IgA and 63% IgG antibodies. Using anti-deamidated gliadin antibodies, the number of false positive IgA and, particularly, IgG results, markedly decreased in the non celiac patients: 21 and 24% respectively with anti-Gliadin (GAF-3X) Euroimmun kit, 7 and 26% with Bindazyme Human Anti-Gliadin (MGP) The Binding Site kit and 0 and 41% with Celiac G+ Immco kit. The new assay which makes use of the physiological complex of tissue transglutaminase cross-linked with deamidated gliadin peptides, called neo-epitope, did not improve the differential diagnosis of celiac disease with 30% of false positive results in IgG (2% in IgA). Using the Inova screening kit, a positive result for IgA and/or IgG anti-deamidated gliadin and/or anti-tissue transglutaminase antibodies was obtained in 24% of the non celiac patients. In conclusion, our study assessed the superiority, in terms of specificity, of anti-deamidated gliadin antibodies, over the conventional anti-gliadin antibodies for the differential diagnosis of celiac disease.

Authors+Show Affiliations

Service de chimie médicale, Centre hospitalier universitaire de Liège, Belgique. laurence.lutteri@chu.ulg.ac.beNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

20348047

Citation

Lutteri, Laurence, et al. "[Anti-deamidated Gliadin Peptides Antibodies and Coeliac Disease: State of Art and Analysis of False-positive Results From Five Assays]." Annales De Biologie Clinique, vol. 68, no. 2, 2010, pp. 149-56.
Lutteri L, Sagot C, Chapelle JP. [Anti-deamidated gliadin peptides antibodies and coeliac disease: state of art and analysis of false-positive results from five assays]. Ann Biol Clin (Paris). 2010;68(2):149-56.
Lutteri, L., Sagot, C., & Chapelle, J. P. (2010). [Anti-deamidated gliadin peptides antibodies and coeliac disease: state of art and analysis of false-positive results from five assays]. Annales De Biologie Clinique, 68(2), pp. 149-56. doi:10.1684/abc.2010.0398.
Lutteri L, Sagot C, Chapelle JP. [Anti-deamidated Gliadin Peptides Antibodies and Coeliac Disease: State of Art and Analysis of False-positive Results From Five Assays]. Ann Biol Clin (Paris). 2010;68(2):149-56. PubMed PMID: 20348047.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Anti-deamidated gliadin peptides antibodies and coeliac disease: state of art and analysis of false-positive results from five assays]. AU - Lutteri,Laurence, AU - Sagot,Clémence, AU - Chapelle,Jean-Paul, PY - 2010/3/30/entrez PY - 2010/3/30/pubmed PY - 2010/6/9/medline SP - 149 EP - 56 JF - Annales de biologie clinique JO - Ann. Biol. Clin. (Paris) VL - 68 IS - 2 N2 - Recently, anti-deamidated gliadin antibodies were proposed for the serological diagnosis of celiac disease. We evaluate the specificity of different anti-deamidated gliadin antibodies ELISA in comparison with conventional anti-native gliadin kits. Serum samples from 46 non celiac patients were analyzed by five different quantitative ELISA for anti-native gliadin, anti-deamidated gliadin and anti-transglutaminase neo-epitope antibodies together with a screening ELISA. Twenty-four percent of the patients demonstrated anti-native gliadin IgA and 63% IgG antibodies. Using anti-deamidated gliadin antibodies, the number of false positive IgA and, particularly, IgG results, markedly decreased in the non celiac patients: 21 and 24% respectively with anti-Gliadin (GAF-3X) Euroimmun kit, 7 and 26% with Bindazyme Human Anti-Gliadin (MGP) The Binding Site kit and 0 and 41% with Celiac G+ Immco kit. The new assay which makes use of the physiological complex of tissue transglutaminase cross-linked with deamidated gliadin peptides, called neo-epitope, did not improve the differential diagnosis of celiac disease with 30% of false positive results in IgG (2% in IgA). Using the Inova screening kit, a positive result for IgA and/or IgG anti-deamidated gliadin and/or anti-tissue transglutaminase antibodies was obtained in 24% of the non celiac patients. In conclusion, our study assessed the superiority, in terms of specificity, of anti-deamidated gliadin antibodies, over the conventional anti-gliadin antibodies for the differential diagnosis of celiac disease. SN - 0003-3898 UR - https://www.unboundmedicine.com/medline/citation/20348047/[Anti_deamidated_gliadin_peptides_antibodies_and_coeliac_disease:_state_of_art_and_analysis_of_false_positive_results_from_five_assays]_ L2 - http://www.jle.com/medline.md?issn=0003-3898&vol=68&iss=2&page=149 DB - PRIME DP - Unbound Medicine ER -